



10-18-04

IPW

Please type a plus sign (+) inside this box →



PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | |
|---|---|---|-------------------|
| TRANSMITTAL FORM (to be used for all correspondence after initial filing) | | Application Number | 10/722,349 |
| | | Filing Date | November 24, 2003 |
| | | First Named Inventor | LAU, ALLAN S. |
| | | Group Art Unit | 1648 |
| | | Examiner Name | Not Yet Assigned |
| Total Number of Pages in This Submission | 8 | Attorney Docket Number | UCSF-285CON5 |
| ENCLOSURES (check all that apply) | | | |
| <input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement SB08a Form <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) | <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Postcard | Remarks |
| SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT | | | |
| Signing Attorney/Agent (Reg. No.) | CAROL L. FRANCIS, 36,513 BOZICEVIC, FIELD & FRANCIS, LLP | | |
| Signature | | | |
| Date | October 14, 2004 | | |

EXPRESS MAIL LABEL NO. EV 519866436 US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Express Mail No. EV 519866436 US

**INFORMATION
DISCLOSURE STATEMENT**

Address to:
Mail Stop
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

| | |
|----------------------|---|
| Attorney Docket | UCSF-285CON5 |
| First Named Inventor | LAU, ALLAN S. |
| Application Number | 10/722,349 |
| Confirmation No. | 4703 |
| Filing Date | November 24, 2003 |
| Group Art Unit | 1648 |
| Examiner Name | Not Yet Assigned |
| Title: | "METHODS FOR ENHANCING THE PRODUCTION OF VIRAL VACCINES IN CELL CULTURE" |

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been viewed and made of record.

All of the references identified herein were disclosed in parent application serial number 09/736,748 filed 12/13/2000 and as such, copies thereof are not included pursuant to the provisions of 37 CFR § 1.98(d).

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. § 102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. UCSF-285CON5 may be charged thereon.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP


Date:

Oct 14, 2004

By:

Carol L. Francis
Carol L. Francis
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|--------------------------|------------------------|--------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Complete if Known | | |
| | | | Application Number | 10/722,349 | |
| | | | Filing Date | November 24, 2003 | |
| | | | First Named Inventor | LAU, ALLAN S. | |
| | | | Art Unit | 1648 | |
| | | | Examiner Name | Not Yet Assigned | |
| Sheet | 1 | of | 6 | Attorney Docket Number | UCSF-285CON5 |

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|--------------------------|--|--|--------------------------------|--|---|
| Examiner Initials' | Cite No. ¹ | Document Number | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | | |
| | | US- RE 33.164 | | 02/13/90 | Brown | |
| | | US- 4.579.821 | | 04/01/86 | Palmiter et al. | |
| | | US- 5.525.513 | | 06/11/96 | Chen | |
| | | US- 5.149.531 | | 09/22/92 | Younger | |
| | | US- 5.840.565 | | 11/24/98 | Lau | |
| | | US- 6.673.591 | | 01/06/04 | Lau | |
| | | US- 6.686.190 | | 02/03/04 | Lau | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|--------------------------------|--|---|----------------|
| Examiner Initials' | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | | EP 0 414 475 | 2/1991 | Chiron Corp. | | |
| | | WO 93 20188 | 10/1993 | Bio Merieux | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|--------------------------|------------------------|--------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | Complete if Known | | |
| | | | Application Number | 10/722,349 | |
| | | | Filing Date | November 24, 2003 | |
| | | | First Named Inventor | LAU, ALLAN S. | |
| | | | Group Art Unit | 1648 | |
| | | | Examiner Name | Not Yet Assigned | |
| Sheet | 2 | of | 6 | Attorney Docket Number | UCSF-285CON5 |

| OTHER ART—NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | Aguzzi et al., "Transgenic and knock-out mice: models of neurological disease.", Brain Pathology (1994) 4:3-20 | |
| | | Barber et al., "The 58-kilodalton inhibitor of the interferon-induced double-stranded RNA-activated protein kinase is a tetratricopeptide repeat protein with oncogenic properties", Proc. Natl. Acad. Sci. USA, (1994) 91:4278-4282 | |
| | | Bowie et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," Science, Vol. 247:1306-1310(1990). | |
| | | Busby et. al., "Isolation of mutant promoters in the Escherichia coli galactose operon using local mutagenesis on cloned DNA fragments", J. Mol. Biol. (1982) 154:197-209 | |
| | | Camper et al., "Implementing transgenic and embryonic stem cell technology to study gene expression, cell-cell interactions and gene function", Biology of Reproduction (1995) 52:246-257 | |
| | | Candal et al., "Possibilities of vaccine manufacture in human diploid cell strains with a serum replacement factor", Biologicals (1991) 19:213-218 | |
| | | Chong et al., "Human p68 kinase exhibits growth suppression in yeast and homology to the translational regulator GCN2", EMBOJ. (1992) 11:1553-1562 | |
| | | Clemens, et al. "PKR-A protein kinase regulated by double-stranded RNA", Int. J. Biochem. Cell Biol. (1997) Vol. 29, no. 7, pp. 945-949 | |
| | | D'Addario et al., "Coordinate enhancement of cytokine gene expression in human immunodeficiency virus type 1-infected promonocytic cells", J. Virol. (1990)64:6080-6089 | |
| | | Deng et al., "Site-directed mutagenesis of virtually any plasmid by eliminating a unique site", Analytical Biochemistry (1992) 200:81-88 | |
| | | Der, S.D., et al., "Involvement of the double-stranded RNA-dependent kinase PKR in interferon expression and interferon-mediated antiviral activity", Proc. Natl. Acad. Sci. USA, Vol. 92:8841-8845 (1995). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|-------------------|------------------------|--------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | Complete if Known | | | |
| | | Application Number | 10/722,349 | | |
| | | Filing Date | November 24, 2003 | | |
| | | First Named Inventor | LAU, ALLAN S. | | |
| | | Group Art Unit | 1648 | | |
| | | Examiner Name | Not Yet Assigned | | |
| Sheet | 3 | of | 6 | Attorney Docket Number | UCSF-285CON5 |

| | | | |
|--|--|--|--|
| | | Du et al., "Mechanisms of transcriptional synergism between distinct virus-inducible enhancer elements", Cell (1993) 74:887-898 | |
| | | Feng et al., "Identification of double-stranded RNA-binding domains in the interferon-induced double-stranded RNA-activated p68 kinase.", Proc Natl Acad Sci USA (1992) 89:5447-5451 | |
| | | Galabru et al., "Autophosphorylation of the protein kinase dependent on double-stranded RNA", J. Biol. Chem. (1987) 262:15538-15544 | |
| | | Green SR et al., "Two RNA-binding motifs in the double-stranded RNA-activated protein kinase, DAI", Genes & Development (1992) 6:2478-2490 | |
| | | Gutterman, "Cytokine therapeutics: lessons from interferon alpha", Proc Natl. Acad. Sci. (1994) 91:1198-1205 | |
| | | Hassel et al., "A sensitive assay for the IFN-regulated 2-5A synthetase enzyme", J Virol Methods (1994) 50:323-334 | |
| | | Henry et al., "Mechanism of interferon action. Translational control and the RNA-dependent protein kinase (PKR): antagonists of PKR enhance the translational activity of mRNAs that include a 161 nucleotide region from reovirus S1 mRNA", J. Biol. Regulators and Homeostatic Agents (1994) 8:1:15-24 | |
| | | Hershey et al., "Translational control in mammalian cells", Ann. Rev. Biochem. (1991) 60:717-755 | |
| | | Hovanessian, Ara G., "The double stranded RNA-activated protein kinase induced by interferon:dsRNA-PK," J. Interferon Res., Vol. 9(6):641-7 (1989). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|-------------------|------------------------|--------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | Complete if Known | | | |
| | | Application Number | 10/722,349 | | |
| | | Filing Date | November 24, 2003 | | |
| | | First Named Inventor | LAU, ALLAN S. | | |
| | | Group Art Unit | 1648 | | |
| | | Examiner Name | Not Yet Assigned | | |
| Sheet | 4 | of | 6 | Attorney Docket Number | UCSF-285CON5 |

| | | |
|--|--|--|
| | Jaramillo, et al., "The interferon system: a review with emphasis on the role of PKR in growth control", Cancer Investigation (1995) (13)3, 327-338. | |
| | Koromilas, et al. "Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase", Science (1992) 257:1685-1689 | |
| | Kumar et al., "Double-stranded RNA-dependent protein kinase activates transcription factor NF-kappa B by phosphorylating I kappa B", Natl. Acad. Sci. USA (1994) 91:6288-6292 | |
| | Lee et al., "The interferon-induced double-stranded RNA-activated human p68 protein kinase inhibits the replication of vaccinia virus", Virol. (1993) 193:1037-1041 | |
| | Lee et al., "The interferon-induced double-stranded RNA-activated human p68 protein kinase potently inhibits protein synthesis in cultured cells", Virology (1993) 192:380-385 | |
| | MacDonald et al., "Development of new cell lines for animal cell biotechnology", Critical Reviews Biotech. (1990) 10:155-178 | |
| | Maran et al., "Blockage of NF-kappa B signaling by selective ablation of an mRNA target by 2-5A antisense chimeras", Science (1994) 265:789-792 | |
| | Marcus et al., "Interferon induction by viruses. XVI. 2-Aminopurine blocks selectively and reversibly an early stage in interferon induction", J. Gen. Virol. (1988) 69:1637-1645 | |
| | Matsuyama et al., "Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development", Cell (1993) 75:83-97 | |
| | McCormack et al., "Mechanism of interferon action motif I of the interferon-induced, RNA-dependent protein kinase (PKR) is sufficient to mediate RNA-binding activity", Virology (1994) 198:92-99 | |
| | McMillan et al., "Mutational analysis of the double-stranded RNA (dsRNA) binding domain of the dsRNA-activated protein kinase, PKR", J. Biol. Chem. (1995) 270:2601-2606 | |
| | Meurs et al., "Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon", Cell (1990) 62:379-390 | |
| | Meurs et al., "Constitutive expression of human double-stranded RNA-activated p68 kinase in murine cells mediates phosphorylation of eukaryotic initiation factor 2 and partial resistance to encephalomyocarditis virus | |
| | Meurs et al., "Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase", Proc. Natl. Acad. Sci. USA (1993) 90:232-236 | |
| | Ozes et al., "Reversal of interferon-gamma-resistant phenotype by poly(I:C): possible involvement of ISGF2 (IRF1) in interferon-gamma-mediated induction of the IDO gene", J. Interferon Res. (1994) 14:25-32 | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|-------------------|------------------------|--------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | Complete if Known | | | |
| | | Application Number | 10/722,349 | | |
| | | Filing Date | November 24, 2003 | | |
| | | First Named Inventor | LAU, ALLAN S. | | |
| | | Group Art Unit | 1648 | | |
| | | Examiner Name | Not Yet Assigned | | |
| Sheet | 5 | of | 6 | Attorney Docket Number | UCSF-285CON5 |

| | | |
|--|--|--|
| | Pearson, "Changing issues of quality control: diploid and non-diploid cell lines", Devel. Biol. Standard. (1992) 76:13-17 | |
| | Peettermans, "Production, quality control and characterization of an inactivated hepatitis A vaccine", J. Vaccine (1992) 10 supp 1:S99-S101 | |
| | Pestka et al., "Interferons and their actions", Ann. Rev. Biochem. (1987) 56:727-777 | |
| | Proud C.G., "PKR: a new name and new roles.", Trends Biochem. Sci. (TIBS), (1995) 20:6:241-246 | |
| | Read et al., "Elevated levels of interferon-induced 2'-5' oligoadenylate synthetase in generalized persistent lymphadenopathy and the acquired immunodeficiency syndrome", J. Infect. Dis. (1985) 152:466-472 | |
| | Robertson et al., "Sequence analysis of the haemagglutinin (HA) of influenza A (H1N1) viruses present in clinical material and comparison with the HA of laboratory-derived virus", J. Gen. Virol. (1991) 72:2671- | |
| | Samuel, Charles E.; Ozato, Keiko, "induction of interferons and interferon-induced genes," Biotherapy (Dordrecht, Neth.), Vol. Date 1994, 8(3/4, Cytokine Yearbook, Vol. 1), 183-187. | |
| | Sen et al., "The interferon system. A bird's eye view of its biochemistry", J. Biol. Chem. (1992) 267:5017-5020 | |
| | Shevitz et al., in Viral Vaccines Mizrahi, A. ed ppl-35 (1990) Wiley-Liss | |
| | Tanaka et al., "Cytokine gene regulation: regulatory cis-elements and DNA binding factors involved in the interferon system", Adv. Immunol. (1992) 52:263-281 | |
| | Tannock et al., "Evaluation of chicken kidney and chicken embryo kidney cultures for the large-scale growth of attenuated influenza virus master strain A/Ann/Arbor/6/60-ca", Vaccine (1985) 3:333-339 | |
| | Taylor et al., "Recent progress in interferon research: molecular mechanisms of regulation, action, and virus circumvention", Virus Research (1990) 15:1-26 | |
| | Thomas et al., "IFN-gamma-mediated antimicrobial response. Indoleamine 2,3-dioxygenase-deficient mutant host cells no longer inhibit intracellular Chlamydia spp. or Toxoplasma growth", J Immunol (1993) | |
| | Visvanathan et al., "Double-stranded RNA activates binding of NF-kappa B to an inducible element in the human beta-interferon promoter", EMBOJ. (1989) 8:1129-1138 | |
| | Williams, "Transcriptional regulation of interferon-stimulated genes", Eur. J. Biochem. (1991) 200:1-11 | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|-------------------|------------------------|--------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | Complete if Known | | | |
| | | Application Number | 10/722,349 | | |
| | | Filing Date | November 24, 2003 | | |
| | | First Named Inventor | LAU, ALLAN S. | | |
| | | Group Art Unit | 1648 | | |
| | | Examiner Name | Not Yet Assigned | | |
| Sheet | 6 | of | 6 | Attorney Docket Number | UCSF-285CON5 |

| | | | |
|--|--|--|--|
| | | Wood et al., "Use of human diploid cells in vaccine production", Biologicals (1990) 18:143-146 | |
| | | Zinn et al., "2-Aminopurine selectively inhibits the induction of beta-interferon, c-fos, and c-myc gene expression", Science (1988) 240:210-213 | |
| | | ZÜRCHER, et al., "Nuclear localization of mouse Mx1 protein is necessary for inhibition of influenza virus", Journal of Virology, (1992), 66:8:5059-5066 | |
| | | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.